Blurbs

Maxim Group Thinks Atossa Therapeutics’ Stock is Going to Recover

Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Therapeutics (ATOSResearch Report) yesterday and set a price target of $4.00. The company’s shares closed last Friday at $0.93, close to its 52-week low of $0.84.

According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -42.6% and a 10.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atossa Therapeutics with a $5.75 average price target.

See the top stocks recommended by analysts >>

Atossa Therapeutics’ market cap is currently $118M and has a P/E ratio of -5.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Read More on ATOS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos